Willis, Mark and Robertson, Neil
2016.
Alemtuzumab for multiple sclerosis.
Current Neurology and Neuroscience Reports
16
, 84.
10.1007/s11910-016-0685-y
![]() |
|
PDF
- Published Version
Available under License Creative Commons Attribution. Download (741kB) | Preview |
Abstract
Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials have demonstrated a dramatic effect on relapse rates as well as a positive effect on radiological disease outcomes and disability measures. Despite a mechanism of action that results in profound lymphopaenia, opportunistic infections are rarely seen and no excess association with malignancy has been identified. However, acquired autoimmune disease (AID) is a common adverse event following treatment, necessitating rigorous monitoring in order to facilitate prompt detection and management. Despite this issue, a unique dosing schedule and durability of effect make alemtuzumab a welcome addition to currently available treatment options for MS.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Subjects: | R Medicine > R Medicine (General) |
Additional Information: | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License |
Publisher: | SpringerLink |
ISSN: | 1528-4042 |
Date of First Compliant Deposit: | 10 November 2016 |
Date of Acceptance: | 1 August 2016 |
Last Modified: | 16 Jul 2019 12:40 |
URI: | http://orca.cf.ac.uk/id/eprint/95967 |
Citation Data
Cited 27 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |